peplomycin and Uterine-Neoplasms

As the treatment of inoperable, radioresistant or recurrent cases of uterine cancer (cervical or endometrial) whose lesions were restricted to the pelvis, internal iliac arterial chemotherapy was carried out and its therapeutic results were evaluated. Thirty three cases including 22 primary and 11 recurrent ones were dealt with this study. Among 33 cases, catheter was introduced to the internal iliac artery via superior gluteal artery in 9, inferior gluteal artery in 22 and lateral umbilical artery in 2 cases. Oncostatics, including mainly cisplatin, adriamycin and pepleomycin, were administered via artery daily or once or three times a week with indwelling of the catheter as long as 7 months in average. Eight patients out of 33 were living with average survival time of 18.2 months following the initiation of intra-arterial chemotherapy. Among 27 cases whose therapeutic effects were evaluable histologically, tumor cells had disappeared as long as at least 4 months in 23, within 4 months in 3 cases and tumor cells continued to be present in one case. In 22 primary cases, 3 were living without evidence of disease, one was living with disease and remaining 18 cases were dead due to other diseases in two cases, distant metastasis in 7 cases, troubles of the primary site in 8 cases and unknown reason (septic shock?) in one case. Four of 11 recurrent cases were living with one case of tumor bearing state. Complete response (CR) was obtained in 5 cases and partial response (PR) in 4 among 9 evaluable recurrent cases. As for the recurrent cases whose main therapy was intra-arterial chemotherapy only, CR was gained in 3 and PR was got in 4 out of 7 cases. Severe side effects were observed in 11, moderate one in 15 and mild one in 6 cases.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Evaluation; Female; Humans; Iliac Artery; Infusions, Intra-Arterial; Middle Aged; Peplomycin; Remission Induction; Uterine Cervical Neoplasms; Uterine Neoplasms

The combination of cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate was used to treat 15 patients with recurrent and metastatic endometrial cancer. Four patients had a complete response and one patient had a partial response, yielding a total response rate of 33%. Five patients had stable disease. The median survival for the whole group was 38 weeks. The median survival for responders was 60 weeks, and that for nonresponders was 21 weeks. The median progression-free survival for the whole group was 17 weeks. The median progression-free survival for responders was 32 weeks, and that for patients with stable disease was 25 weeks. The toxic reactions noted were primarily nausea, vomiting, and myelosuppression. The combination of cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate has modest effectiveness in the treatment of metastatic or recurrent carcinoma of the endometrium.

Topics: Aclarubicin; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Female; Humans; Megestrol; Megestrol Acetate; Neoplasm Recurrence, Local; Peplomycin; Uterine Neoplasms

A case of metastatic uterine papillary carcinoma with elevated serum carcinoembryonic antigen (CEA) is reported. The patient presented with ascites and pleural effusions and with a high level of CEA (258 ng/ml) 3 months after primary surgical resection and postoperative irradiation had been performed. Her complete response, although temporary, to two kinds of combination chemotherapy was evaluated using serial estimations of the serum CEA.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoembryonic Antigen; Carcinoma, Papillary; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Peplomycin; Uterine Neoplasms; Vinblastine

Eight patients with gynecologic cancer (cervix: 6, corpus: 1 and vulva: 1) were treated with combination chemotherapy, PPM therapy consisting of continuously infused PEP 4mg/m2 days 1-5, CDDP 13 mg/m2 days 1-5, and MMC 3mg/m2 day 1. This was repeated every three to five weeks. Six of the eight patients were evaluable, two had a complete response and one had a partial response, for an overall response rate of 50%. Because of hematological toxicity, blood transfusion was carried out in four patients. Nephrotoxicity and pulmonary toxicity were slight. Nausea and vomiting were controlled with dexamethasone and domperidone. PPM therapy is considered to be an effective and useful combination chemotherapy for patients with gynecologic cancer.

Topics: Adenocarcinoma; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Mitomycin; Mitomycins; Peplomycin; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms

Based on Peplomycin-induced cell cycle distribution analyzed by a flow-cytemetry using HeLa S-3 and SNG-M cells in vitro, we investigated reasonable periods and kinds of drug combined with pepleomycin (PEP). Changes in both the PEP treatment time and dosage produced a redistribution which decreases the number of cells in the G1 phase and increased the number of cells in the S and G2-M phases. The period with the maximum number of cells in the S phase was 12 hours in the HeLa S-3 and 16 hours in the SNG-M and, that in the G2-M phases, 16 hours in the HeLa S-3 and 22 hours in the SNG-M after the treatment. In the combination of the pep with CIS-DDP 4-hydroperoxy cyclophosphamide Adriamycin (ADR) and ACNU, the cytotoxic potency of the four drugs were CIS-DDP greater than 4-Hydroperoxy cyclophosphamide greater than ADR greater than ACNU in the HeLa S-3 and 4-Hydroperoxy cyclophosphamide greater than CIS-DDP greater than ADR greater than ACNU in the SNG-M. This suggests that the Cis and 4-Hydroperoxy cyclophosphamide were adequate for the combination with the PEP. The period of the combination should be at the time of the greatest accumulation of cells in the G2-M phase, because the pep effectively produced the G2-M partial synchronization. These results suggest that the combination chemotherapy should be based on the analysis of the cell cycle.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Line; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Flow Cytometry; Humans; In Vitro Techniques; Interphase; Nimustine; Nitrosourea Compounds; Peplomycin; Uterine Cervical Neoplasms; Uterine Neoplasms

In cancer therapy, the authors have attempted to decrease the side effects. Since 1975 they have used immuno-thermo-chemotherapy(so-called ITC therapy). At this time the ITC therapy is used in combination with induced-hypertension-chemotherapy (IHC therapy). This new approach has been applied to patients with terminal or advanced malignancy, which have been unsuccessfully treated by conventional ITC therapy. This report compares the clinical effects of conventional ITC therapy those of new modality in the same patient. The clinical results are 6 cases of I-A and one case of I-B according to Karnofsky's criteria. This New modality is more effective than the conventional ITC therapy in all 7 patients.

Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Pressure; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Hyperthermia, Induced; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms; Peplomycin; Uterine Neoplasms; Vincristine

Various types of human gynecological cultured tumor cells were tested for the sensitivity to Peplomycin (PEP), an effective antitumor antibiotic for squamous cell carcinomas, by the regrowth assay method together with morphological observation. Bleomycin-hydrolase activity of these cell lines was also compared in cell-free extracts by assaying the conversion of Bleomycin into its deamidated from (HPLC method). SKG-I, SKG-II, SKG-IIIb cells derived from squamous cell carcinoma of the cervix and RKN cells derived from myosarcoma of the ovary were much more sensitive to PEP than other cell lines. PEP was found to be mainly a time-dependent drug, but also concentration dependent. The effect of PEP on cell morphology was characterized by the appearance of enlarged cells and swelling nuclei. The specific activities of Bleomycin-hydrolase in SKG-I, SKG-II, SKG-IIIb cells were shown to be relatively lower than that in other cell lines. These results suggested that cervical squamous carcinoma cells and ovarian myosarcoma cells were sensitive to PEP and Bleomycin-hydrolase activity was one of factors which decided the PEP sensitivity of human cultured tumor cells.

Topics: Antibiotics, Antineoplastic; Bleomycin; Cell Division; Cell Line; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance; Female; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Peplomycin; Uterine Cervical Neoplasms; Uterine Neoplasms

A combination immunochemotherapy regimen containing cisplatin (20 mg, days 1-5), peplomycin (20 mg, days 2, 9, 16), +/- vinblastine (5 mg, days 1, 2), and picibanil (3-5 KE/week) was performed in twelve patients with advanced or recurrent uterine and ovarian cancers under intravenous hyperalimentation (IVH), except one patient receiving peplomycin by a continuous infusion method using IVH bag (10 mg/day for 5 days). This regimen was repeated every three weeks. Five (71.4%) of seven evaluable patients showed partial response. No patients yielded the complete disappearance of disease. No severe and lethal pulmonary or renal dysfunction occurred and all was well tolerated. In a regimen without vinblastine, myelosuppression, especially thrombocytopenia, occurred later compared to the regimen including vinblastine.

Topics: Adenocarcinoma; Aged; Biological Products; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Humans; Immunotherapy; Middle Aged; Ovarian Neoplasms; Peplomycin; Picibanil; Uterine Cervical Neoplasms; Uterine Neoplasms; Vinblastine